

The Translational Hematology Cluster
presents

Therapy Development in Malignant Blood Disease

14th of December, 2016
Conference room, 3rd floor, BBB

- | | |
|-------------|--|
| 12:00-12:10 | Prof. Lars Herfindal
<i>- Opening words</i> |
| 12:10-12:35 | Andrea Trentani, PhD
<i>- Synergy between hydroxyurea and 6-mercaptopurine, two old drugs with antagonistic profiles</i> |
| 12:35-13:15 | Trung Ha, MSc
<i>- Preclinical activity and molecular mechanisms of resazurin in AML</i> |
| 13:15-13:45 | Prof. Øystein Bruserud
<i>- Midostaurin treatment in AML</i> |
| 13:45-14:15 | Short break - Light seasonal refreshments |
| 14:15-14:30 | Reidun Æsøy, PhD
<i>- Potential novel anti-leukemic agents among Iodinin analogues</i> |
| 14:30-14:55 | Sahba Safiee, MSc
<i>- MDS and new treatment options</i> |
| 14:55-15:20 | Pascal Gelebart, PhD
<i>- Development of novel therapies for aggressive B-cell lymphoma</i> |
| 15:20-15:40 | Misbah Sabir, MSc
<i>- BCI compounds: development of new Flt3 targeted inhibitors</i> |
| 15:40-15:55 | Monica Hellesøy, PhD
<i>- Development of BGB324</i> |
| 15:55-16:00 | Prof. Lars Herfindal
<i>- Concluding remarks</i> |